ClinicaliQ Trial Snapshot
- ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis — Recruiting • Phase III • Rare Diseases • NCT05878860.
- Gene therapy for inherited eye disease causing vision loss in males, testing safety and effectiveness in children and adults.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will evaluate the safety and efficacy of ATSN-201 in subjects ≥ 5 years of age with RS1-associated X-linked retinoschisis (XLRS). Conditions: X-linked Retinoschisis Interventions: ATSN-201 Lead Sponsor: Atsena Therapeutics Inc. Planned Enrollment: 97 participants